Anti-tumor and anti-osteolysis effects of the metronomic use of zoledronic acid in primary and metastatic breast cancer mouse models
Publication in refereed journal

Times Cited
Web of Science12WOS source URL (as at 05/05/2021) Click here for the latest count
Altmetrics Information

Other information
AbstractThis study aims to determine the effect of metronomic (0.0125 mg/kg twice a week for 4 weeks) zoledronic acid (ZOL) on cancer propagation and osteolysis against both metastatic and primary breast cancer in mice model. From our results, metronomic ZOL resulted in a significant reduction of tumor burden and did not promote lung or liver metastasis. The metronomic ZOL appeared to be more effective than the conventional regimen (0.1 mg/kg once in 4 weeks) in reducing breast cancer tumor burden, and regulating its movement to lung and liver. This dosing schedule of ZOL showed great potential against metastatic breast cancer. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
All Author(s) ListLuo KW, Ko CH, Yue GGL, Lee MYY, Siu WS, Lee JKM, Shum WT, Fung KP, Leung PC, Li G, Evdokiou A, Lau CBS
Journal nameCancer Letters
Volume Number339
Issue Number1
Pages42 - 48
LanguagesEnglish-United Kingdom
KeywordsAnti-osteolysis; Conventional; Metastasis; Metronomic; Zoledronic acid
Web of Science Subject CategoriesOncology; ONCOLOGY

Last updated on 2021-06-05 at 01:44